D. Boral Capital Initiates Coverage on Omeros (NASDAQ:OMER)

D. Boral Capital assumed coverage on shares of Omeros (NASDAQ:OMER) in a research report issued to clients and investors on Monday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $36.00 price target on the biopharmaceutical company’s stock. D. Boral Capital’s target price would suggest a potential upside of 249.18% from the company’s current price.

OMER has been the subject of several other reports. Rodman & Renshaw began coverage on Omeros in a research note on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Thursday. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. Finally, RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Omeros presently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Stock Up 0.7 %

NASDAQ:OMER opened at $10.31 on Monday. The stock has a market cap of $597.46 million, a PE ratio of -4.46 and a beta of 1.97. The business’s 50-day simple moving average is $7.09 and its two-hundred day simple moving average is $5.20. Omeros has a 52 week low of $2.61 and a 52 week high of $13.60.

Hedge Funds Weigh In On Omeros

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC raised its position in shares of Omeros by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock valued at $5,318,000 after buying an additional 6,839 shares in the last quarter. State Street Corp lifted its stake in shares of Omeros by 0.3% in the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after purchasing an additional 3,839 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Omeros by 4.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock worth $1,926,000 after purchasing an additional 18,454 shares during the period. Bank of New York Mellon Corp increased its position in shares of Omeros by 16.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after purchasing an additional 31,081 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in Omeros by 6.1% during the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock valued at $454,000 after buying an additional 6,435 shares during the period. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.